id	sid	tid	token	lemma	pos
dpc-4967	1	1	dermatology	dermatology	NOUN
dpc-4967	1	2	:	:	PUNCT
dpc-4967	1	3	practical	practical	ADJ
dpc-4967	1	4	and	and	CCONJ
dpc-4967	1	5	conceptual	conceptual	ADJ
dpc-4967	1	6	research	research	NOUN
dpc-4967	1	7	letter	letter	NOUN
dpc-4967	2	1	|	|	ADV
dpc-4967	2	2	dermatol	dermatol	ADJ
dpc-4967	2	3	pract	pract	NOUN
dpc-4967	2	4	concept	concept	NOUN
dpc-4967	2	5	.	.	PUNCT
dpc-4967	3	1	2025;15(1):4967	2025;15(1):4967	NUM
dpc-4967	3	2	1	1	NUM
dpc-4967	3	3	lichen	lichen	NOUN
dpc-4967	3	4	planus	planus	ADJ
dpc-4967	3	5	-	-	PUNCT
dpc-4967	3	6	like	like	ADJ
dpc-4967	3	7	exanthema	exanthema	NOUN
dpc-4967	3	8	induced	induce	VERB
dpc-4967	3	9	by	by	ADP
dpc-4967	3	10	anti	anti	ADJ
dpc-4967	3	11	-	-	ADJ
dpc-4967	3	12	pd-1	pd-1	ADJ
dpc-4967	3	13	and	and	CCONJ
dpc-4967	3	14	anti	anti	ADJ
dpc-4967	3	15	-	-	ADJ
dpc-4967	3	16	lag-3	lag-3	X
dpc-4967	3	17	combination	combination	NOUN
dpc-4967	3	18	immunotherapy	immunotherapy	NOUN
dpc-4967	3	19	could	could	AUX
dpc-4967	3	20	potentially	potentially	ADV
dpc-4967	3	21	predict	predict	VERB
dpc-4967	3	22	the	the	DET
dpc-4967	3	23	treatment	treatment	NOUN
dpc-4967	3	24	response	response	NOUN
dpc-4967	3	25	in	in	ADP
dpc-4967	3	26	metastatic	metastatic	ADJ
dpc-4967	3	27	melanoma	melanoma	PROPN
dpc-4967	3	28	marek	marek	PROPN
dpc-4967	3	29	pásek1	pásek1	PROPN
dpc-4967	3	30	,	,	PUNCT
dpc-4967	3	31	eva	eva	PROPN
dpc-4967	3	32	sticová2	sticová2	PROPN
dpc-4967	3	33	,	,	PUNCT
dpc-4967	3	34	emanuel	emanuel	PROPN
dpc-4967	3	35	marques3,4	marques3,4	PROPN
dpc-4967	3	36	,	,	PUNCT
dpc-4967	3	37	vojtěch	vojtěch	NOUN
dpc-4967	3	38	tretera1	tretera1	PROPN
dpc-4967	3	39	,	,	PUNCT
dpc-4967	3	40	petr	petr	PROPN
dpc-4967	3	41	arenberger1	arenberger1	PROPN
dpc-4967	3	42	,	,	PUNCT
dpc-4967	3	43	monika	monika	PROPN
dpc-4967	3	44	arenbergerová1	arenbergerová1	PROPN
dpc-4967	3	45	1	1	NUM
dpc-4967	3	46	department	department	NOUN
dpc-4967	3	47	of	of	ADP
dpc-4967	3	48	dermatology	dermatology	NOUN
dpc-4967	3	49	and	and	CCONJ
dpc-4967	3	50	venereology	venereology	NOUN
dpc-4967	3	51	,	,	PUNCT
dpc-4967	3	52	third	third	ADJ
dpc-4967	3	53	faculty	faculty	NOUN
dpc-4967	3	54	of	of	ADP
dpc-4967	3	55	medicine	medicine	NOUN
dpc-4967	3	56	,	,	PUNCT
dpc-4967	3	57	charles	charles	PROPN
dpc-4967	3	58	university	university	PROPN
dpc-4967	3	59	and	and	CCONJ
dpc-4967	3	60	královské	královské	PROPN
dpc-4967	3	61	vinohrady	vinohrady	PROPN
dpc-4967	3	62	university	university	NOUN
dpc-4967	3	63	hospital	hospital	NOUN
dpc-4967	3	64	,	,	PUNCT
dpc-4967	3	65	prague	prague	PROPN
dpc-4967	3	66	,	,	PUNCT
dpc-4967	3	67	czech	czech	PROPN
dpc-4967	3	68	republic	republic	NOUN
dpc-4967	3	69	2	2	NUM
dpc-4967	3	70	department	department	NOUN
dpc-4967	3	71	of	of	ADP
dpc-4967	3	72	pathology	pathology	PROPN
dpc-4967	3	73	,	,	PUNCT
dpc-4967	3	74	third	third	ADJ
dpc-4967	3	75	faculty	faculty	NOUN
dpc-4967	3	76	of	of	ADP
dpc-4967	3	77	medicine	medicine	NOUN
dpc-4967	3	78	,	,	PUNCT
dpc-4967	3	79	charles	charles	PROPN
dpc-4967	3	80	university	university	PROPN
dpc-4967	3	81	,	,	PUNCT
dpc-4967	3	82	and	and	CCONJ
dpc-4967	3	83	královské	královské	PROPN
dpc-4967	3	84	vinohrady	vinohrady	PROPN
dpc-4967	3	85	university	university	NOUN
dpc-4967	3	86	hospital	hospital	NOUN
dpc-4967	3	87	,	,	PUNCT
dpc-4967	3	88	prague	prague	PROPN
dpc-4967	3	89	,	,	PUNCT
dpc-4967	3	90	czech	czech	PROPN
dpc-4967	3	91	republic	republic	PROPN
dpc-4967	3	92	3	3	NUM
dpc-4967	3	93	department	department	NOUN
dpc-4967	3	94	of	of	ADP
dpc-4967	3	95	dermatology	dermatology	NOUN
dpc-4967	3	96	and	and	CCONJ
dpc-4967	3	97	venereology	venereology	NOUN
dpc-4967	3	98	,	,	PUNCT
dpc-4967	3	99	st	st	PROPN
dpc-4967	3	100	.	.	PROPN
dpc-4967	3	101	joseph	joseph	PROPN
dpc-4967	3	102	local	local	PROPN
dpc-4967	3	103	health	health	PROPN
dpc-4967	3	104	unit	unit	NOUN
dpc-4967	3	105	,	,	PUNCT
dpc-4967	3	106	lisbon	lisbon	PROPN
dpc-4967	3	107	,	,	PUNCT
dpc-4967	3	108	portugal	portugal	PROPN
dpc-4967	3	109	4	4	NUM
dpc-4967	3	110	department	department	NOUN
dpc-4967	3	111	of	of	ADP
dpc-4967	3	112	dermatology	dermatology	NOUN
dpc-4967	3	113	and	and	CCONJ
dpc-4967	3	114	venereology	venereology	NOUN
dpc-4967	3	115	,	,	PUNCT
dpc-4967	3	116	nova	nova	PROPN
dpc-4967	3	117	medical	medical	PROPN
dpc-4967	3	118	school	school	PROPN
dpc-4967	3	119	,	,	PUNCT
dpc-4967	3	120	university	university	PROPN
dpc-4967	3	121	lisbon	lisbon	PROPN
dpc-4967	3	122	,	,	PUNCT
dpc-4967	3	123	portugal	portugal	PROPN
dpc-4967	3	124	key	key	ADJ
dpc-4967	3	125	words	word	NOUN
dpc-4967	3	126	:	:	PUNCT
dpc-4967	3	127	melanoma	melanoma	NOUN
dpc-4967	3	128	,	,	PUNCT
dpc-4967	3	129	anti	anti	ADJ
dpc-4967	3	130	-	-	ADJ
dpc-4967	3	131	pd-1	pd-1	ADJ
dpc-4967	3	132	,	,	PUNCT
dpc-4967	3	133	anti	anti	ADJ
dpc-4967	3	134	-	-	ADJ
dpc-4967	3	135	lag-3	lag-3	X
dpc-4967	3	136	,	,	PUNCT
dpc-4967	3	137	adverse	adverse	ADJ
dpc-4967	3	138	events	event	NOUN
dpc-4967	3	139	citation	citation	NOUN
dpc-4967	3	140	:	:	PUNCT
dpc-4967	3	141	pásek	pásek	PROPN
dpc-4967	3	142	m	m	PRON
dpc-4967	3	143	,	,	PUNCT
dpc-4967	3	144	sticová	sticová	PROPN
dpc-4967	3	145	e	e	NOUN
dpc-4967	3	146	,	,	PUNCT
dpc-4967	3	147	marques	marques	PROPN
dpc-4967	3	148	e	e	PROPN
dpc-4967	3	149	,	,	PUNCT
dpc-4967	3	150	tretera	tretera	NOUN
dpc-4967	3	151	v	v	NOUN
dpc-4967	3	152	,	,	PUNCT
dpc-4967	3	153	arenberger	arenberger	ADV
dpc-4967	3	154	p	p	NOUN
dpc-4967	3	155	,	,	PUNCT
dpc-4967	3	156	arenbergerová	arenbergerová	DET
dpc-4967	3	157	m.	m.	NOUN
dpc-4967	3	158	lichen	lichen	NOUN
dpc-4967	3	159	planus	planus	PROPN
dpc-4967	3	160	-	-	PUNCT
dpc-4967	3	161	like	like	ADJ
dpc-4967	3	162	exanthema	exanthema	NOUN
dpc-4967	3	163	induced	induce	VERB
dpc-4967	3	164	by	by	ADP
dpc-4967	3	165	anti	anti	ADJ
dpc-4967	3	166	-	-	ADJ
dpc-4967	3	167	pd-1	pd-1	ADJ
dpc-4967	3	168	and	and	CCONJ
dpc-4967	3	169	anti	anti	ADJ
dpc-4967	3	170	-	-	ADJ
dpc-4967	3	171	lag-3	lag-3	X
dpc-4967	3	172	combination	combination	NOUN
dpc-4967	3	173	immunotherapy	immunotherapy	NOUN
dpc-4967	3	174	could	could	AUX
dpc-4967	3	175	potentially	potentially	ADV
dpc-4967	3	176	predict	predict	VERB
dpc-4967	3	177	the	the	DET
dpc-4967	3	178	treatment	treatment	NOUN
dpc-4967	3	179	response	response	NOUN
dpc-4967	3	180	in	in	ADP
dpc-4967	3	181	metastatic	metastatic	ADJ
dpc-4967	3	182	melanoma	melanoma	NOUN
dpc-4967	3	183	.	.	PUNCT
dpc-4967	4	1	dermatol	dermatol	NOUN
dpc-4967	4	2	pract	pract	PROPN
dpc-4967	4	3	concept	concept	NOUN
dpc-4967	4	4	.	.	PUNCT
dpc-4967	5	1	2025;15(1):4967	2025;15(1):4967	NUM
dpc-4967	5	2	.	.	PUNCT
dpc-4967	6	1	doi	doi	PROPN
dpc-4967	6	2	:	:	PUNCT
dpc-4967	6	3	https://doi.org/10.5826/dpc.1501a4967	https://doi.org/10.5826/dpc.1501a4967	PROPN
dpc-4967	6	4	accepted	accept	VERB
dpc-4967	6	5	:	:	PUNCT
dpc-4967	6	6	november	november	PROPN
dpc-4967	6	7	4	4	NUM
dpc-4967	6	8	,	,	PUNCT
dpc-4967	6	9	2024	2024	NUM
dpc-4967	6	10	;	;	PUNCT
dpc-4967	6	11	published	publish	VERB
dpc-4967	6	12	:	:	PUNCT
dpc-4967	7	1	january	january	PROPN
dpc-4967	7	2	2025	2025	NUM
dpc-4967	7	3	copyright	copyright	NOUN
dpc-4967	7	4	:	:	PUNCT
dpc-4967	7	5	©	©	PROPN
dpc-4967	7	6	2024	2024	NUM
dpc-4967	7	7	pásek	pásek	NOUN
dpc-4967	7	8	et	et	PROPN
dpc-4967	7	9	al	al	PROPN
dpc-4967	7	10	.	.	PUNCT
dpc-4967	8	1	this	this	PRON
dpc-4967	8	2	is	be	AUX
dpc-4967	8	3	an	an	DET
dpc-4967	8	4	open	open	ADJ
dpc-4967	8	5	-	-	PUNCT
dpc-4967	8	6	access	access	NOUN
dpc-4967	8	7	article	article	NOUN
dpc-4967	8	8	distributed	distribute	VERB
dpc-4967	8	9	under	under	ADP
dpc-4967	8	10	the	the	DET
dpc-4967	8	11	terms	term	NOUN
dpc-4967	8	12	of	of	ADP
dpc-4967	8	13	the	the	DET
dpc-4967	8	14	creative	creative	ADJ
dpc-4967	8	15	commons	common	NOUN
dpc-4967	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4967	8	17	license	license	NOUN
dpc-4967	8	18	(	(	PUNCT
dpc-4967	8	19	by	by	ADP
dpc-4967	8	20	-	-	PUNCT
dpc-4967	8	21	nc-4.0	nc-4.0	NOUN
dpc-4967	8	22	)	)	PUNCT
dpc-4967	8	23	,	,	PUNCT
dpc-4967	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4967	8	25	,	,	PUNCT
dpc-4967	8	26	which	which	PRON
dpc-4967	8	27	permits	permit	VERB
dpc-4967	8	28	unrestricted	unrestricted	ADJ
dpc-4967	8	29	noncommercial	noncommercial	ADJ
dpc-4967	8	30	use	use	NOUN
dpc-4967	8	31	,	,	PUNCT
dpc-4967	8	32	distribution	distribution	NOUN
dpc-4967	8	33	,	,	PUNCT
dpc-4967	8	34	and	and	CCONJ
dpc-4967	8	35	reproduction	reproduction	NOUN
dpc-4967	8	36	in	in	ADP
dpc-4967	8	37	any	any	DET
dpc-4967	8	38	medium	medium	NOUN
dpc-4967	8	39	,	,	PUNCT
dpc-4967	8	40	provided	provide	VERB
dpc-4967	8	41	the	the	DET
dpc-4967	8	42	original	original	ADJ
dpc-4967	8	43	authors	author	NOUN
dpc-4967	8	44	and	and	CCONJ
dpc-4967	8	45	source	source	NOUN
dpc-4967	8	46	are	be	AUX
dpc-4967	8	47	credited	credit	VERB
dpc-4967	8	48	.	.	PUNCT
dpc-4967	9	1	funding	funding	NOUN
dpc-4967	9	2	:	:	PUNCT
dpc-4967	9	3	none	none	NOUN
dpc-4967	9	4	.	.	PUNCT
dpc-4967	10	1	competing	compete	VERB
dpc-4967	10	2	interests	interest	NOUN
dpc-4967	10	3	:	:	PUNCT
dpc-4967	10	4	none	none	NOUN
dpc-4967	10	5	.	.	PUNCT
dpc-4967	11	1	authorship	authorship	NOUN
dpc-4967	11	2	:	:	PUNCT
dpc-4967	11	3	all	all	DET
dpc-4967	11	4	authors	author	NOUN
dpc-4967	11	5	have	have	AUX
dpc-4967	11	6	contributed	contribute	VERB
dpc-4967	11	7	significantly	significantly	ADV
dpc-4967	11	8	to	to	ADP
dpc-4967	11	9	this	this	DET
dpc-4967	11	10	publication	publication	NOUN
dpc-4967	11	11	.	.	PUNCT
dpc-4967	12	1	corresponding	correspond	VERB
dpc-4967	12	2	author	author	NOUN
dpc-4967	12	3	:	:	PUNCT
dpc-4967	12	4	marek	marek	PROPN
dpc-4967	12	5	pásek	pásek	PROPN
dpc-4967	12	6	,	,	PUNCT
dpc-4967	12	7	srobarova	srobarova	VERB
dpc-4967	12	8	1150/50	1150/50	NUM
dpc-4967	12	9	,	,	PUNCT
dpc-4967	12	10	prague	prague	NOUN
dpc-4967	12	11	10	10	NUM
dpc-4967	12	12	,	,	PUNCT
dpc-4967	12	13	czech	czech	PROPN
dpc-4967	12	14	republic	republic	NOUN
dpc-4967	12	15	.	.	PUNCT
dpc-4967	13	1	phone	phone	NOUN
dpc-4967	13	2	+420	+420	NUM
dpc-4967	13	3	 	 	SPACE
dpc-4967	13	4	606	606	NUM
dpc-4967	13	5	 	 	SPACE
dpc-4967	13	6	606	606	NUM
dpc-4967	13	7	346	346	NUM
dpc-4967	13	8	.	.	PUNCT
dpc-4967	14	1	e	e	X
dpc-4967	14	2	-	-	NOUN
dpc-4967	14	3	mail	mail	NOUN
dpc-4967	14	4	:	:	PUNCT
dpc-4967	14	5	marek.pasek@seznam.cz	marek.pasek@seznam.cz	ADJ
dpc-4967	14	6	introduction	introduction	NOUN
dpc-4967	14	7	a	a	DET
dpc-4967	14	8	combination	combination	NOUN
dpc-4967	14	9	therapy	therapy	NOUN
dpc-4967	14	10	using	use	VERB
dpc-4967	14	11	nivolumab	nivolumab	NOUN
dpc-4967	14	12	(	(	PUNCT
dpc-4967	14	13	anti	anti	ADJ
dpc-4967	14	14	-	-	ADJ
dpc-4967	14	15	pd-1	pd-1	ADJ
dpc-4967	14	16	)	)	PUNCT
dpc-4967	14	17	and	and	CCONJ
dpc-4967	14	18	relatlimab	relatlimab	NOUN
dpc-4967	14	19	(	(	PUNCT
dpc-4967	14	20	anti	anti	NOUN
dpc-4967	14	21	-	-	ADJ
dpc-4967	14	22	lag-3	lag-3	NUM
dpc-4967	14	23	)	)	PUNCT
dpc-4967	14	24	has	have	AUX
dpc-4967	14	25	been	be	AUX
dpc-4967	14	26	compared	compare	VERB
dpc-4967	14	27	head	head	NOUN
dpc-4967	14	28	-	-	PUNCT
dpc-4967	14	29	to	to	ADP
dpc-4967	14	30	-	-	PUNCT
dpc-4967	14	31	head	head	NOUN
dpc-4967	14	32	with	with	ADP
dpc-4967	14	33	a	a	DET
dpc-4967	14	34	monotherapy	monotherapy	NOUN
dpc-4967	14	35	of	of	ADP
dpc-4967	14	36	nivolumab	nivolumab	NOUN
dpc-4967	14	37	and	and	CCONJ
dpc-4967	14	38	shown	show	VERB
dpc-4967	14	39	a	a	DET
dpc-4967	14	40	statistically	statistically	ADV
dpc-4967	14	41	significant	significant	ADJ
dpc-4967	14	42	improvement	improvement	NOUN
dpc-4967	14	43	in	in	ADP
dpc-4967	14	44	progression	progression	NOUN
dpc-4967	14	45	-	-	PUNCT
dpc-4967	14	46	free	free	ADJ
dpc-4967	14	47	survival	survival	NOUN
dpc-4967	14	48	rate	rate	NOUN
dpc-4967	14	49	,	,	PUNCT
dpc-4967	14	50	with	with	ADP
dpc-4967	14	51	minimal	minimal	ADJ
dpc-4967	14	52	increase	increase	NOUN
dpc-4967	14	53	in	in	ADP
dpc-4967	14	54	toxicity	toxicity	NOUN
dpc-4967	14	55	[	[	X
dpc-4967	14	56	1	1	NUM
dpc-4967	14	57	]	]	PUNCT
dpc-4967	14	58	.	.	PUNCT
dpc-4967	15	1	based	base	VERB
dpc-4967	15	2	on	on	ADP
dpc-4967	15	3	these	these	DET
dpc-4967	15	4	unprecedented	unprecedented	ADJ
dpc-4967	15	5	results	result	NOUN
dpc-4967	15	6	,	,	PUNCT
dpc-4967	15	7	nivolumab	nivolumab	NOUN
dpc-4967	15	8	and	and	CCONJ
dpc-4967	15	9	relatlimab	relatlimab	NOUN
dpc-4967	15	10	are	be	AUX
dpc-4967	15	11	currently	currently	ADV
dpc-4967	15	12	considered	consider	VERB
dpc-4967	15	13	the	the	DET
dpc-4967	15	14	new	new	ADJ
dpc-4967	15	15	gold	gold	NOUN
dpc-4967	15	16	standard	standard	NOUN
dpc-4967	15	17	in	in	ADP
dpc-4967	15	18	first	first	ADJ
dpc-4967	15	19	-	-	PUNCT
dpc-4967	15	20	line	line	NOUN
dpc-4967	15	21	treatment	treatment	NOUN
dpc-4967	15	22	of	of	ADP
dpc-4967	15	23	advanced	advanced	ADJ
dpc-4967	15	24	melanoma	melanoma	NOUN
dpc-4967	16	1	[	[	X
dpc-4967	16	2	1,2	1,2	NUM
dpc-4967	16	3	]	]	PUNCT
dpc-4967	16	4	.	.	PUNCT
dpc-4967	17	1	case	case	NOUN
dpc-4967	17	2	presentation	presentation	NOUN
dpc-4967	17	3	a	a	DET
dpc-4967	17	4	50	50	NUM
dpc-4967	17	5	-	-	PUNCT
dpc-4967	17	6	year	year	NOUN
dpc-4967	17	7	-	-	PUNCT
dpc-4967	17	8	old	old	ADJ
dpc-4967	17	9	male	male	NOUN
dpc-4967	17	10	transferred	transfer	VERB
dpc-4967	17	11	to	to	ADP
dpc-4967	17	12	our	our	PRON
dpc-4967	17	13	department	department	NOUN
dpc-4967	17	14	after	after	ADP
dpc-4967	17	15	a	a	DET
dpc-4967	17	16	resection	resection	NOUN
dpc-4967	17	17	of	of	ADP
dpc-4967	17	18	melanoma	melanoma	PROPN
dpc-4967	17	19	lymph	lymph	NOUN
dpc-4967	17	20	node	node	VERB
dpc-4967	17	21	metastasis	metastasis	NOUN
dpc-4967	17	22	in	in	ADP
dpc-4967	17	23	the	the	DET
dpc-4967	17	24	left	left	ADJ
dpc-4967	17	25	groin	groin	NOUN
dpc-4967	17	26	area	area	NOUN
dpc-4967	17	27	.	.	PUNCT
dpc-4967	18	1	we	we	PRON
dpc-4967	18	2	initially	initially	ADV
dpc-4967	18	3	performed	perform	VERB
dpc-4967	18	4	a	a	DET
dpc-4967	18	5	whole	whole	ADJ
dpc-4967	18	6	-	-	PUNCT
dpc-4967	18	7	body	body	NOUN
dpc-4967	18	8	ct	ct	NOUN
dpc-4967	18	9	scan	scan	NOUN
dpc-4967	18	10	and	and	CCONJ
dpc-4967	18	11	mri	mri	NOUN
dpc-4967	18	12	of	of	ADP
dpc-4967	18	13	the	the	DET
dpc-4967	18	14	brain	brain	NOUN
dpc-4967	18	15	which	which	PRON
dpc-4967	18	16	revealed	reveal	VERB
dpc-4967	18	17	the	the	DET
dpc-4967	18	18	involvement	involvement	NOUN
dpc-4967	18	19	of	of	ADP
dpc-4967	18	20	multiple	multiple	ADJ
dpc-4967	18	21	lymph	lymph	NOUN
dpc-4967	18	22	nodes	node	NOUN
dpc-4967	18	23	in	in	ADP
dpc-4967	18	24	the	the	DET
dpc-4967	18	25	left	left	ADJ
dpc-4967	18	26	groin	groin	NOUN
dpc-4967	18	27	area	area	NOUN
dpc-4967	18	28	and	and	CCONJ
dpc-4967	18	29	axilla	axilla	NOUN
dpc-4967	18	30	,	,	PUNCT
dpc-4967	18	31	para	para	NOUN
dpc-4967	18	32	-	-	PUNCT
dpc-4967	18	33	iliac	iliac	NOUN
dpc-4967	18	34	and	and	CCONJ
dpc-4967	18	35	para	para	NOUN
dpc-4967	18	36	-	-	PUNCT
dpc-4967	18	37	aorta	aorta	NOUN
dpc-4967	18	38	left	leave	VERB
dpc-4967	18	39	,	,	PUNCT
dpc-4967	18	40	in	in	ADP
dpc-4967	18	41	the	the	DET
dpc-4967	18	42	mediastinum	mediastinum	NOUN
dpc-4967	18	43	,	,	PUNCT
dpc-4967	18	44	and	and	CCONJ
dpc-4967	18	45	under	under	ADP
dpc-4967	18	46	the	the	DET
dpc-4967	18	47	left	left	ADJ
dpc-4967	18	48	clavicle	clavicle	NOUN
dpc-4967	18	49	.	.	PUNCT
dpc-4967	19	1	furthermore	furthermore	ADV
dpc-4967	19	2	,	,	PUNCT
dpc-4967	19	3	we	we	PRON
dpc-4967	19	4	performed	perform	VERB
dpc-4967	19	5	dermoscopic	dermoscopic	NOUN
dpc-4967	19	6	,	,	PUNCT
dpc-4967	19	7	otorhinolaryngological	otorhinolaryngological	ADJ
dpc-4967	19	8	,	,	PUNCT
dpc-4967	19	9	and	and	CCONJ
dpc-4967	19	10	urological	urological	ADJ
dpc-4967	19	11	examinations	examination	NOUN
dpc-4967	19	12	,	,	PUNCT
dpc-4967	19	13	which	which	PRON
dpc-4967	19	14	did	do	VERB
dpc-4967	19	15	not	not	PART
dpc-4967	19	16	2	2	NUM
dpc-4967	19	17	research	research	NOUN
dpc-4967	19	18	letter	letter	NOUN
dpc-4967	20	1	|	|	ADV
dpc-4967	20	2	dermatol	dermatol	ADJ
dpc-4967	20	3	pract	pract	NOUN
dpc-4967	20	4	concept	concept	NOUN
dpc-4967	20	5	.	.	PUNCT
dpc-4967	21	1	2025;15(1):4967	2025;15(1):4967	PRON
dpc-4967	21	2	identify	identify	VERB
dpc-4967	21	3	any	any	DET
dpc-4967	21	4	trace	trace	NOUN
dpc-4967	21	5	of	of	ADP
dpc-4967	21	6	primary	primary	ADJ
dpc-4967	21	7	melanoma	melanoma	NOUN
dpc-4967	21	8	.	.	PUNCT
dpc-4967	22	1	the	the	DET
dpc-4967	22	2	testing	testing	NOUN
dpc-4967	22	3	of	of	ADP
dpc-4967	22	4	the	the	DET
dpc-4967	22	5	braf	braf	NOUN
dpc-4967	22	6	mutation	mutation	NOUN
dpc-4967	22	7	(	(	PUNCT
dpc-4967	22	8	braf	braf	NOUN
dpc-4967	22	9	v600e	v600e	VERB
dpc-4967	22	10	mutated	mutate	VERB
dpc-4967	22	11	)	)	PUNCT
dpc-4967	22	12	and	and	CCONJ
dpc-4967	22	13	initial	initial	ADJ
dpc-4967	22	14	blood	blood	NOUN
dpc-4967	22	15	tests	test	NOUN
dpc-4967	22	16	(	(	PUNCT
dpc-4967	22	17	lactate	lactate	NOUN
dpc-4967	22	18	dehydrogenase	dehydrogenase	NOUN
dpc-4967	22	19	in	in	ADP
dpc-4967	22	20	the	the	DET
dpc-4967	22	21	normal	normal	ADJ
dpc-4967	22	22	range	range	NOUN
dpc-4967	22	23	)	)	PUNCT
dpc-4967	22	24	were	be	AUX
dpc-4967	22	25	performed	perform	VERB
dpc-4967	22	26	.	.	PUNCT
dpc-4967	23	1	the	the	DET
dpc-4967	23	2	conclusive	conclusive	ADJ
dpc-4967	23	3	findings	finding	NOUN
dpc-4967	23	4	confirmed	confirm	VERB
dpc-4967	23	5	a	a	DET
dpc-4967	23	6	diagnosis	diagnosis	NOUN
dpc-4967	23	7	of	of	ADP
dpc-4967	23	8	a	a	DET
dpc-4967	23	9	metastatic	metastatic	ADJ
dpc-4967	23	10	malignant	malignant	ADJ
dpc-4967	23	11	melanoma	melanoma	NOUN
dpc-4967	23	12	of	of	ADP
dpc-4967	23	13	unknown	unknown	ADJ
dpc-4967	23	14	primary	primary	ADJ
dpc-4967	23	15	origin	origin	NOUN
dpc-4967	23	16	in	in	ADP
dpc-4967	23	17	stage	stage	NOUN
dpc-4967	23	18	4a	4a	NOUN
dpc-4967	23	19	.	.	PUNCT
dpc-4967	24	1	according	accord	VERB
dpc-4967	24	2	to	to	ADP
dpc-4967	24	3	the	the	DET
dpc-4967	24	4	guidelines	guideline	NOUN
dpc-4967	24	5	,	,	PUNCT
dpc-4967	24	6	we	we	PRON
dpc-4967	24	7	decided	decide	VERB
dpc-4967	24	8	to	to	PART
dpc-4967	24	9	start	start	VERB
dpc-4967	24	10	first	first	ADJ
dpc-4967	24	11	-	-	PUNCT
dpc-4967	24	12	line	line	NOUN
dpc-4967	24	13	of	of	ADP
dpc-4967	24	14	systemic	systemic	ADJ
dpc-4967	24	15	therapy	therapy	NOUN
dpc-4967	24	16	with	with	ADP
dpc-4967	24	17	nivolumab	nivolumab	NOUN
dpc-4967	24	18	480	480	NUM
dpc-4967	24	19	mg	mg	NOUN
dpc-4967	24	20	and	and	CCONJ
dpc-4967	24	21	relatlimab	relatlimab	VERB
dpc-4967	24	22	160	160	NUM
dpc-4967	24	23	mg	mg	NOUN
dpc-4967	24	24	every	every	DET
dpc-4967	24	25	4	4	NUM
dpc-4967	24	26	weeks	week	NOUN
dpc-4967	24	27	[	[	X
dpc-4967	24	28	2	2	NUM
dpc-4967	24	29	]	]	PUNCT
dpc-4967	24	30	.	.	PUNCT
dpc-4967	25	1	the	the	DET
dpc-4967	25	2	first	first	ADJ
dpc-4967	25	3	3	3	NUM
dpc-4967	25	4	infusions	infusion	NOUN
dpc-4967	25	5	resulted	result	VERB
dpc-4967	25	6	without	without	ADP
dpc-4967	25	7	any	any	DET
dpc-4967	25	8	complications	complication	NOUN
dpc-4967	25	9	.	.	PUNCT
dpc-4967	26	1	however	however	ADV
dpc-4967	26	2	,	,	PUNCT
dpc-4967	26	3	after	after	ADP
dpc-4967	26	4	the	the	DET
dpc-4967	26	5	fourth	fourth	ADJ
dpc-4967	26	6	infusion	infusion	NOUN
dpc-4967	26	7	,	,	PUNCT
dpc-4967	26	8	an	an	DET
dpc-4967	26	9	extensive	extensive	ADJ
dpc-4967	26	10	exanthema	exanthema	NOUN
dpc-4967	26	11	with	with	ADP
dpc-4967	26	12	pink	pink	ADJ
dpc-4967	26	13	itchy	itchy	ADJ
dpc-4967	26	14	flat	flat	ADV
dpc-4967	26	15	-	-	PUNCT
dpc-4967	26	16	topped	top	VERB
dpc-4967	26	17	lichenoid	lichenoid	PROPN
dpc-4967	26	18	papules	papule	NOUN
dpc-4967	26	19	appeared	appear	VERB
dpc-4967	26	20	on	on	ADP
dpc-4967	26	21	the	the	DET
dpc-4967	26	22	scalp	scalp	NOUN
dpc-4967	26	23	,	,	PUNCT
dpc-4967	26	24	décolletage	décolletage	NOUN
dpc-4967	26	25	,	,	PUNCT
dpc-4967	26	26	upper	upper	ADJ
dpc-4967	26	27	third	third	NOUN
dpc-4967	26	28	of	of	ADP
dpc-4967	26	29	the	the	DET
dpc-4967	26	30	back	back	NOUN
dpc-4967	26	31	,	,	PUNCT
dpc-4967	26	32	arms	arm	NOUN
dpc-4967	26	33	,	,	PUNCT
dpc-4967	26	34	and	and	CCONJ
dpc-4967	26	35	thighs	thigh	NOUN
dpc-4967	26	36	(	(	PUNCT
dpc-4967	26	37	figure	figure	NOUN
dpc-4967	26	38	1	1	NUM
dpc-4967	26	39	,	,	PUNCT
dpc-4967	26	40	a	a	PRON
dpc-4967	26	41	and	and	CCONJ
dpc-4967	26	42	b	b	NOUN
dpc-4967	26	43	)	)	PUNCT
dpc-4967	26	44	.	.	PUNCT
dpc-4967	27	1	the	the	DET
dpc-4967	27	2	mucosa	mucosa	NOUN
dpc-4967	27	3	and	and	CCONJ
dpc-4967	27	4	nail	nail	NOUN
dpc-4967	27	5	plates	plate	NOUN
dpc-4967	27	6	were	be	AUX
dpc-4967	27	7	intact	intact	ADJ
dpc-4967	27	8	.	.	PUNCT
dpc-4967	28	1	dermoscopic	dermoscopic	NOUN
dpc-4967	28	2	examination	examination	NOUN
dpc-4967	28	3	showed	show	VERB
dpc-4967	28	4	wickham	wickham	PROPN
dpc-4967	28	5	striae	striae	PROPN
dpc-4967	28	6	,	,	PUNCT
dpc-4967	28	7	red	red	ADJ
dpc-4967	28	8	dots	dot	NOUN
dpc-4967	28	9	,	,	PUNCT
dpc-4967	28	10	and	and	CCONJ
dpc-4967	28	11	radial	radial	ADJ
dpc-4967	28	12	capillaries	capillary	NOUN
dpc-4967	28	13	[	[	X
dpc-4967	28	14	3	3	NUM
dpc-4967	28	15	]	]	PUNCT
dpc-4967	28	16	(	(	PUNCT
dpc-4967	28	17	figure	figure	NOUN
dpc-4967	28	18	1c	1c	NOUN
dpc-4967	28	19	)	)	PUNCT
dpc-4967	28	20	.	.	PUNCT
dpc-4967	29	1	this	this	DET
dpc-4967	29	2	immune	immune	NOUN
dpc-4967	29	3	-	-	PUNCT
dpc-4967	29	4	mediated	mediate	VERB
dpc-4967	29	5	adverse	adverse	ADJ
dpc-4967	29	6	event	event	NOUN
dpc-4967	29	7	(	(	PUNCT
dpc-4967	29	8	ae	ae	PROPN
dpc-4967	29	9	)	)	PUNCT
dpc-4967	29	10	was	be	AUX
dpc-4967	29	11	evaluated	evaluate	VERB
dpc-4967	29	12	as	as	ADP
dpc-4967	29	13	grade	grade	NOUN
dpc-4967	29	14	ii	ii	NOUN
dpc-4967	29	15	[	[	X
dpc-4967	29	16	4	4	NUM
dpc-4967	29	17	]	]	PUNCT
dpc-4967	29	18	.	.	PUNCT
dpc-4967	30	1	a	a	DET
dpc-4967	30	2	punch	punch	NOUN
dpc-4967	30	3	biopsy	biopsy	NOUN
dpc-4967	30	4	was	be	AUX
dpc-4967	30	5	performed	perform	VERB
dpc-4967	30	6	and	and	CCONJ
dpc-4967	30	7	subsequently	subsequently	ADV
dpc-4967	30	8	,	,	PUNCT
dpc-4967	30	9	a	a	DET
dpc-4967	30	10	histological	histological	ADJ
dpc-4967	30	11	evaluation	evaluation	NOUN
dpc-4967	30	12	confirmed	confirm	VERB
dpc-4967	30	13	the	the	DET
dpc-4967	30	14	diagnosis	diagnosis	NOUN
dpc-4967	30	15	of	of	ADP
dpc-4967	30	16	a	a	DET
dpc-4967	30	17	lichen	lichen	NOUN
dpc-4967	30	18	planus	planus	NOUN
dpc-4967	30	19	-	-	PUNCT
dpc-4967	30	20	like	like	ADJ
dpc-4967	30	21	exanthema	exanthema	NOUN
dpc-4967	30	22	(	(	PUNCT
dpc-4967	30	23	figure	figure	NOUN
dpc-4967	30	24	1d	1d	NUM
dpc-4967	30	25	)	)	PUNCT
dpc-4967	30	26	.	.	PUNCT
dpc-4967	31	1	topical	topical	ADJ
dpc-4967	31	2	therapy	therapy	NOUN
dpc-4967	31	3	with	with	ADP
dpc-4967	31	4	clobetasol	clobetasol	NOUN
dpc-4967	31	5	propionate	propionate	NOUN
dpc-4967	31	6	,	,	PUNCT
dpc-4967	31	7	in	in	ADP
dpc-4967	31	8	combination	combination	NOUN
dpc-4967	31	9	with	with	ADP
dpc-4967	31	10	bilastine	bilastine	NOUN
dpc-4967	31	11	20	20	NUM
dpc-4967	31	12	mg	mg	NOUN
dpc-4967	31	13	per	per	ADP
dpc-4967	31	14	day	day	NOUN
dpc-4967	31	15	,	,	PUNCT
dpc-4967	31	16	was	be	AUX
dpc-4967	31	17	initiated	initiate	VERB
dpc-4967	31	18	,	,	PUNCT
dpc-4967	31	19	which	which	PRON
dpc-4967	31	20	led	lead	VERB
dpc-4967	31	21	to	to	ADP
dpc-4967	31	22	a	a	DET
dpc-4967	31	23	fast	fast	ADJ
dpc-4967	31	24	decrease	decrease	NOUN
dpc-4967	31	25	in	in	ADP
dpc-4967	31	26	pruritus	pruritus	PROPN
dpc-4967	31	27	.	.	PUNCT
dpc-4967	32	1	due	due	ADP
dpc-4967	32	2	to	to	ADP
dpc-4967	32	3	the	the	DET
dpc-4967	32	4	promising	promising	ADJ
dpc-4967	32	5	effects	effect	NOUN
dpc-4967	32	6	of	of	ADP
dpc-4967	32	7	clobetasole	clobetasole	NOUN
dpc-4967	32	8	,	,	PUNCT
dpc-4967	32	9	we	we	PRON
dpc-4967	32	10	decided	decide	VERB
dpc-4967	32	11	not	not	PART
dpc-4967	32	12	to	to	PART
dpc-4967	32	13	interrupt	interrupt	VERB
dpc-4967	32	14	the	the	DET
dpc-4967	32	15	oncological	oncological	ADJ
dpc-4967	32	16	treatment	treatment	NOUN
dpc-4967	32	17	.	.	PUNCT
dpc-4967	33	1	on	on	ADP
dpc-4967	33	2	the	the	DET
dpc-4967	33	3	first	first	ADJ
dpc-4967	33	4	re	re	NOUN
dpc-4967	33	5	-	-	NOUN
dpc-4967	33	6	staging	staging	NOUN
dpc-4967	33	7	,	,	PUNCT
dpc-4967	33	8	after	after	ADP
dpc-4967	33	9	12	12	NUM
dpc-4967	33	10	weeks	week	NOUN
dpc-4967	33	11	of	of	ADP
dpc-4967	33	12	therapy	therapy	NOUN
dpc-4967	33	13	,	,	PUNCT
dpc-4967	33	14	a	a	DET
dpc-4967	33	15	partial	partial	ADJ
dpc-4967	33	16	response	response	NOUN
dpc-4967	33	17	was	be	AUX
dpc-4967	33	18	achieved	achieve	VERB
dpc-4967	33	19	.	.	PUNCT
dpc-4967	34	1	conclusions	conclusion	NOUN
dpc-4967	34	2	based	base	VERB
dpc-4967	34	3	on	on	ADP
dpc-4967	34	4	the	the	DET
dpc-4967	34	5	available	available	ADJ
dpc-4967	34	6	data	datum	NOUN
dpc-4967	34	7	,	,	PUNCT
dpc-4967	34	8	mainly	mainly	ADV
dpc-4967	34	9	related	relate	VERB
dpc-4967	34	10	to	to	ADP
dpc-4967	34	11	anti	anti	ADJ
dpc-4967	34	12	-	-	ADJ
dpc-4967	34	13	pd-1	pd-1	ADJ
dpc-4967	34	14	+	+	ADJ
dpc-4967	34	15	/anti	/anti	ADJ
dpc-4967	34	16	-	-	PUNCT
dpc-4967	34	17	ctla-4	ctla-4	NOUN
dpc-4967	34	18	immunotherapy	immunotherapy	NOUN
dpc-4967	34	19	,	,	PUNCT
dpc-4967	34	20	there	there	PRON
dpc-4967	34	21	appears	appear	VERB
dpc-4967	34	22	to	to	PART
dpc-4967	34	23	be	be	AUX
dpc-4967	34	24	a	a	DET
dpc-4967	34	25	correlation	correlation	NOUN
dpc-4967	34	26	between	between	ADP
dpc-4967	34	27	cutaneous	cutaneous	ADJ
dpc-4967	34	28	immune	immune	NOUN
dpc-4967	34	29	-	-	PUNCT
dpc-4967	34	30	mediated	mediate	VERB
dpc-4967	34	31	aes	aes	NOUN
dpc-4967	34	32	,	,	PUNCT
dpc-4967	34	33	such	such	ADJ
dpc-4967	34	34	as	as	ADP
dpc-4967	34	35	lichen	lichen	NOUN
dpc-4967	34	36	planus	planus	NOUN
dpc-4967	34	37	-	-	PUNCT
dpc-4967	34	38	like	like	ADJ
dpc-4967	34	39	exanthema	exanthema	NOUN
dpc-4967	34	40	etc	etc	X
dpc-4967	34	41	.	.	X
dpc-4967	34	42	,	,	PUNCT
dpc-4967	34	43	and	and	CCONJ
dpc-4967	34	44	a	a	DET
dpc-4967	34	45	better	well	ADJ
dpc-4967	34	46	prognosis	prognosis	NOUN
dpc-4967	34	47	in	in	ADP
dpc-4967	34	48	patients	patient	NOUN
dpc-4967	34	49	with	with	ADP
dpc-4967	34	50	advanced	advanced	ADJ
dpc-4967	34	51	melanoma	melanoma	NOUN
dpc-4967	34	52	[	[	X
dpc-4967	34	53	5	5	NUM
dpc-4967	34	54	]	]	PUNCT
dpc-4967	34	55	.	.	PUNCT
dpc-4967	35	1	as	as	SCONJ
dpc-4967	35	2	our	our	PRON
dpc-4967	35	3	case	case	NOUN
dpc-4967	35	4	may	may	AUX
dpc-4967	35	5	have	have	AUX
dpc-4967	35	6	shown	show	VERB
dpc-4967	35	7	,	,	PUNCT
dpc-4967	35	8	it	it	PRON
dpc-4967	35	9	seems	seem	VERB
dpc-4967	35	10	that	that	SCONJ
dpc-4967	35	11	cutaneous	cutaneous	ADJ
dpc-4967	35	12	aes	aes	PROPN
dpc-4967	35	13	do	do	AUX
dpc-4967	35	14	potentially	potentially	ADV
dpc-4967	35	15	also	also	ADV
dpc-4967	35	16	have	have	VERB
dpc-4967	35	17	the	the	DET
dpc-4967	35	18	same	same	ADJ
dpc-4967	35	19	positive	positive	ADJ
dpc-4967	35	20	prognostic	prognostic	ADJ
dpc-4967	35	21	capabilities	capability	NOUN
dpc-4967	35	22	in	in	ADP
dpc-4967	35	23	patients	patient	NOUN
dpc-4967	35	24	with	with	ADP
dpc-4967	35	25	a	a	DET
dpc-4967	35	26	combination	combination	NOUN
dpc-4967	35	27	treatment	treatment	NOUN
dpc-4967	35	28	using	use	VERB
dpc-4967	35	29	nivolumab	nivolumab	NOUN
dpc-4967	35	30	and	and	CCONJ
dpc-4967	35	31	relatlimab	relatlimab	NOUN
dpc-4967	35	32	.	.	PUNCT
dpc-4967	36	1	ethics	ethic	NOUN
dpc-4967	36	2	statement	statement	NOUN
dpc-4967	36	3	:	:	PUNCT
dpc-4967	36	4	the	the	DET
dpc-4967	36	5	patient	patient	NOUN
dpc-4967	36	6	voluntarily	voluntarily	ADV
dpc-4967	36	7	signed	sign	VERB
dpc-4967	36	8	consent	consent	NOUN
dpc-4967	36	9	for	for	ADP
dpc-4967	36	10	the	the	DET
dpc-4967	36	11	publication	publication	NOUN
dpc-4967	36	12	of	of	ADP
dpc-4967	36	13	the	the	DET
dpc-4967	36	14	case	case	NOUN
dpc-4967	36	15	.	.	PUNCT
dpc-4967	37	1	figure	figure	NOUN
dpc-4967	37	2	1	1	NUM
dpc-4967	37	3	.	.	PUNCT
dpc-4967	38	1	(	(	PUNCT
dpc-4967	38	2	a	a	X
dpc-4967	38	3	)	)	PUNCT
dpc-4967	38	4	overview	overview	NOUN
dpc-4967	38	5	of	of	ADP
dpc-4967	38	6	the	the	DET
dpc-4967	38	7	clinical	clinical	ADJ
dpc-4967	38	8	picture	picture	NOUN
dpc-4967	38	9	of	of	ADP
dpc-4967	38	10	the	the	DET
dpc-4967	38	11	lichen	lichen	NOUN
dpc-4967	38	12	planus	planus	ADJ
dpc-4967	38	13	-	-	PUNCT
dpc-4967	38	14	like	like	ADJ
dpc-4967	38	15	exanthema	exanthema	NOUN
dpc-4967	38	16	induced	induce	VERB
dpc-4967	38	17	by	by	ADP
dpc-4967	38	18	nivolumab	nivolumab	NOUN
dpc-4967	38	19	and	and	CCONJ
dpc-4967	38	20	relatlimab	relatlimab	NOUN
dpc-4967	38	21	.	.	PUNCT
dpc-4967	39	1	(	(	PUNCT
dpc-4967	39	2	b	b	X
dpc-4967	39	3	)	)	PUNCT
dpc-4967	39	4	clinical	clinical	ADJ
dpc-4967	39	5	presentation	presentation	NOUN
dpc-4967	39	6	of	of	ADP
dpc-4967	39	7	lichenoid	lichenoid	PROPN
dpc-4967	39	8	papules	papule	NOUN
dpc-4967	39	9	on	on	ADP
dpc-4967	39	10	the	the	DET
dpc-4967	39	11	right	right	ADJ
dpc-4967	39	12	arm	arm	NOUN
dpc-4967	39	13	.	.	PUNCT
dpc-4967	40	1	(	(	PUNCT
dpc-4967	40	2	c	c	X
dpc-4967	40	3	)	)	PUNCT
dpc-4967	40	4	dermoscopic	dermoscopic	NOUN
dpc-4967	40	5	picture	picture	NOUN
dpc-4967	40	6	of	of	ADP
dpc-4967	40	7	lichenoid	lichenoid	PROPN
dpc-4967	40	8	papules	papule	NOUN
dpc-4967	40	9	.	.	PUNCT
dpc-4967	41	1	(	(	PUNCT
dpc-4967	41	2	d	d	X
dpc-4967	41	3	)	)	PUNCT
dpc-4967	41	4	histological	histological	ADJ
dpc-4967	41	5	picture	picture	NOUN
dpc-4967	41	6	(	(	PUNCT
dpc-4967	41	7	h&e	h&e	PROPN
dpc-4967	41	8	,	,	PUNCT
dpc-4967	41	9	magnification	magnification	NOUN
dpc-4967	41	10	×200	×200	PROPN
dpc-4967	41	11	)	)	PUNCT
dpc-4967	41	12	.	.	PUNCT
dpc-4967	42	1	lichenoid	lichenoid	PROPN
dpc-4967	42	2	interface	interface	PROPN
dpc-4967	42	3	dermatitis	dermatitis	NOUN
dpc-4967	42	4	with	with	ADP
dpc-4967	42	5	patchy	patchy	ADJ
dpc-4967	42	6	lymphocytic	lymphocytic	ADJ
dpc-4967	42	7	infiltrate	infiltrate	NOUN
dpc-4967	42	8	with	with	ADP
dpc-4967	42	9	some	some	DET
dpc-4967	42	10	eosinophils	eosinophil	NOUN
dpc-4967	42	11	and	and	CCONJ
dpc-4967	42	12	plasma	plasma	NOUN
dpc-4967	42	13	cells	cell	NOUN
dpc-4967	42	14	in	in	ADP
dpc-4967	42	15	the	the	DET
dpc-4967	42	16	superficial	superficial	ADJ
dpc-4967	42	17	dermis	dermis	NOUN
dpc-4967	42	18	.	.	PUNCT
dpc-4967	43	1	research	research	NOUN
dpc-4967	43	2	letter	letter	NOUN
dpc-4967	43	3	|	|	ADV
dpc-4967	43	4	dermatol	dermatol	ADJ
dpc-4967	43	5	pract	pract	NOUN
dpc-4967	43	6	concept	concept	NOUN
dpc-4967	43	7	.	.	PUNCT
dpc-4967	44	1	2025;15(1):4967	2025;15(1):4967	NUM
dpc-4967	44	2	3	3	NUM
dpc-4967	44	3	doi	doi	NOUN
dpc-4967	44	4	:	:	PUNCT
dpc-4967	44	5	10.1136	10.1136	NUM
dpc-4967	44	6	/	/	SYM
dpc-4967	44	7	bcr-2015	bcr-2015	NOUN
dpc-4967	44	8	-	-	PUNCT
dpc-4967	44	9	213923	213923	NUM
dpc-4967	44	10	.	.	PUNCT
dpc-4967	45	1	pmid	pmid	NOUN
dpc-4967	45	2	:	:	PUNCT
dpc-4967	45	3	26759406	26759406	NUM
dpc-4967	45	4	.	.	PUNCT
dpc-4967	46	1	pmcid	pmcid	NOUN
dpc-4967	46	2	:	:	PUNCT
dpc-4967	46	3	pmc4716428	pmc4716428	PROPN
dpc-4967	46	4	.	.	PUNCT
dpc-4967	47	1	4	4	X
dpc-4967	47	2	.	.	X
dpc-4967	47	3	national	national	PROPN
dpc-4967	47	4	cancer	cancer	PROPN
dpc-4967	47	5	institute	institute	PROPN
dpc-4967	47	6	,	,	PUNCT
dpc-4967	47	7	national	national	PROPN
dpc-4967	47	8	institutes	institutes	PROPN
dpc-4967	47	9	of	of	ADP
dpc-4967	47	10	health	health	NOUN
dpc-4967	47	11	,	,	PUNCT
dpc-4967	47	12	us	us	PROPN
dpc-4967	47	13	department	department	PROPN
dpc-4967	47	14	of	of	ADP
dpc-4967	47	15	health	health	PROPN
dpc-4967	47	16	and	and	CCONJ
dpc-4967	47	17	human	human	ADJ
dpc-4967	47	18	services	service	NOUN
dpc-4967	47	19	.	.	PUNCT
dpc-4967	48	1	common	common	ADJ
dpc-4967	48	2	terminology	terminology	NOUN
dpc-4967	48	3	criteria	criterion	NOUN
dpc-4967	48	4	for	for	ADP
dpc-4967	48	5	adverse	adverse	ADJ
dpc-4967	48	6	events	event	NOUN
dpc-4967	48	7	(	(	PUNCT
dpc-4967	48	8	ctcae	ctcae	NOUN
dpc-4967	48	9	)	)	PUNCT
dpc-4967	48	10	,	,	PUNCT
dpc-4967	48	11	ver	ver	NOUN
dpc-4967	48	12	.	.	PROPN
dpc-4967	49	1	5.0	5.0	NUM
dpc-4967	49	2	.	.	X
dpc-4967	49	3	2017	2017	NUM
dpc-4967	49	4	.	.	PUNCT
dpc-4967	50	1	available	available	ADJ
dpc-4967	50	2	from	from	ADP
dpc-4967	50	3	:	:	PUNCT
dpc-4967	50	4	https://ctep.cancer.gov/protocoldevelopment/electronic	https://ctep.cancer.gov/protocoldevelopment/electronic	ADJ
dpc-4967	50	5	_	_	SYM
dpc-4967	50	6	applications	application	NOUN
dpc-4967	50	7	/	/	SYM
dpc-4967	50	8	docs	doc	NOUN
dpc-4967	50	9	/	/	SYM
dpc-4967	50	10	ctcae_v5_quick_reference_8.5x11.pdf	ctcae_v5_quick_reference_8.5x11.pdf	NOUN
dpc-4967	50	11	accessed	access	VERB
dpc-4967	50	12	april	april	PROPN
dpc-4967	50	13	3	3	NUM
dpc-4967	50	14	,	,	PUNCT
dpc-4967	50	15	2023	2023	NUM
dpc-4967	50	16	.	.	PUNCT
dpc-4967	51	1	5	5	NUM
dpc-4967	51	2	.	.	X
dpc-4967	51	3	nikolaou	nikolaou	PROPN
dpc-4967	51	4	v	v	PROPN
dpc-4967	51	5	,	,	PUNCT
dpc-4967	51	6	tsimpidakis	tsimpidakis	PROPN
dpc-4967	51	7	a	a	PROPN
dpc-4967	51	8	,	,	PUNCT
dpc-4967	51	9	stratigos	stratigos	NOUN
dpc-4967	51	10	a.	a.	NOUN
dpc-4967	51	11	cutaneous	cutaneous	ADJ
dpc-4967	51	12	adverse	adverse	ADJ
dpc-4967	51	13	reactions	reaction	NOUN
dpc-4967	51	14	of	of	ADP
dpc-4967	51	15	immunotherapy	immunotherapy	NOUN
dpc-4967	51	16	in	in	ADP
dpc-4967	51	17	patients	patient	NOUN
dpc-4967	51	18	with	with	ADP
dpc-4967	51	19	advanced	advanced	ADJ
dpc-4967	51	20	melanoma	melanoma	NOUN
dpc-4967	51	21	.	.	PUNCT
dpc-4967	52	1	cancers	cancer	NOUN
dpc-4967	52	2	(	(	PUNCT
dpc-4967	52	3	basel	basel	PROPN
dpc-4967	52	4	)	)	PUNCT
dpc-4967	52	5	.	.	PUNCT
dpc-4967	53	1	2023;15(7):2084	2023;15(7):2084	PROPN
dpc-4967	53	2	.	.	PUNCT
dpc-4967	54	1	doi	doi	NOUN
dpc-4967	54	2	:	:	PUNCT
dpc-4967	54	3	10.3390	10.3390	NUM
dpc-4967	54	4	/	/	SYM
dpc-4967	54	5	cancers	cancer	NOUN
dpc-4967	54	6	15072084	15072084	NUM
dpc-4967	54	7	.	.	PUNCT
dpc-4967	55	1	pmid	pmid	NOUN
dpc-4967	55	2	:	:	PUNCT
dpc-4967	55	3	37046745	37046745	NUM
dpc-4967	55	4	.	.	PUNCT
dpc-4967	56	1	pmcid	pmcid	NOUN
dpc-4967	56	2	:	:	PUNCT
dpc-4967	56	3	pmc10093334	pmc10093334	NOUN
dpc-4967	56	4	.	.	PUNCT
dpc-4967	57	1	references	reference	NOUN
dpc-4967	57	2	1	1	NUM
dpc-4967	57	3	.	.	PUNCT
dpc-4967	57	4	tawbi	tawbi	PROPN
dpc-4967	57	5	ha	ha	INTJ
dpc-4967	57	6	,	,	PUNCT
dpc-4967	57	7	schadendorf	schadendorf	PROPN
dpc-4967	57	8	d	d	PROPN
dpc-4967	57	9	,	,	PUNCT
dpc-4967	57	10	lipson	lipson	PROPN
dpc-4967	57	11	ej	ej	PROPN
dpc-4967	57	12	,	,	PUNCT
dpc-4967	57	13	et	et	PROPN
dpc-4967	57	14	al	al	PROPN
dpc-4967	57	15	.	.	PUNCT
dpc-4967	57	16	relativity-047	relativity-047	PROPN
dpc-4967	57	17	investigators	investigator	NOUN
dpc-4967	57	18	.	.	PUNCT
dpc-4967	58	1	relatlimab	relatlimab	NOUN
dpc-4967	58	2	and	and	CCONJ
dpc-4967	58	3	nivolumab	nivolumab	NOUN
dpc-4967	58	4	versus	versus	ADP
dpc-4967	58	5	nivolumab	nivolumab	NOUN
dpc-4967	58	6	in	in	ADP
dpc-4967	58	7	untreated	untreated	ADJ
dpc-4967	58	8	advanced	advanced	ADJ
dpc-4967	58	9	melanoma	melanoma	NOUN
dpc-4967	58	10	.	.	PUNCT
dpc-4967	59	1	n	n	PRON
dpc-4967	59	2	engl	engl	PROPN
dpc-4967	59	3	j	j	PROPN
dpc-4967	59	4	med	med	PROPN
dpc-4967	59	5	.	.	PUNCT
dpc-4967	60	1	2022;386(1	2022;386(1	NUM
dpc-4967	60	2	):	):	PUNCT
dpc-4967	60	3	24	24	NUM
dpc-4967	60	4	-	-	SYM
dpc-4967	60	5	34	34	NUM
dpc-4967	60	6	.	.	PUNCT
dpc-4967	61	1	doi	doi	NOUN
dpc-4967	61	2	:	:	PUNCT
dpc-4967	61	3	10.1056	10.1056	NUM
dpc-4967	61	4	/	/	SYM
dpc-4967	61	5	nejmoa2109970	nejmoa2109970	PROPN
dpc-4967	61	6	.	.	PUNCT
dpc-4967	62	1	pmid	pmid	NOUN
dpc-4967	62	2	:	:	PUNCT
dpc-4967	62	3	34986285	34986285	NUM
dpc-4967	62	4	.	.	PUNCT
dpc-4967	63	1	pmcid	pmcid	NOUN
dpc-4967	63	2	:	:	PUNCT
dpc-4967	63	3	pmc9844513	pmc9844513	NOUN
dpc-4967	63	4	.	.	PUNCT
dpc-4967	64	1	2	2	X
dpc-4967	64	2	.	.	X
dpc-4967	64	3	seth	seth	PROPN
dpc-4967	64	4	r	r	PROPN
dpc-4967	64	5	,	,	PUNCT
dpc-4967	64	6	agarwala	agarwala	PROPN
dpc-4967	64	7	ss	ss	PROPN
dpc-4967	64	8	,	,	PUNCT
dpc-4967	64	9	messersmith	messersmith	PROPN
dpc-4967	64	10	h	h	PROPN
dpc-4967	64	11	,	,	PUNCT
dpc-4967	64	12	et	et	PROPN
dpc-4967	64	13	al	al	PROPN
dpc-4967	64	14	.	.	PUNCT
dpc-4967	65	1	systemic	systemic	ADJ
dpc-4967	65	2	therapy	therapy	NOUN
dpc-4967	65	3	for	for	ADP
dpc-4967	65	4	melanoma	melanoma	NOUN
dpc-4967	65	5	:	:	PUNCT
dpc-4967	65	6	asco	asco	ADJ
dpc-4967	65	7	guideline	guideline	NOUN
dpc-4967	65	8	update	update	NOUN
dpc-4967	65	9	.	.	PUNCT
dpc-4967	66	1	j	j	PROPN
dpc-4967	66	2	clin	clin	PROPN
dpc-4967	66	3	oncol	oncol	PROPN
dpc-4967	66	4	.	.	PUNCT
dpc-4967	67	1	2023;41(30	2023;41(30	NUM
dpc-4967	67	2	):	):	PUNCT
dpc-4967	67	3	4794	4794	NUM
dpc-4967	67	4	-	-	SYM
dpc-4967	67	5	20	20	NUM
dpc-4967	67	6	.	.	PUNCT
dpc-4967	68	1	doi	doi	NOUN
dpc-4967	68	2	:	:	PUNCT
dpc-4967	68	3	10.1200	10.1200	NUM
dpc-4967	68	4	/	/	SYM
dpc-4967	68	5	jco.23.01136	jco.23.01136	NOUN
dpc-4967	68	6	.	.	PUNCT
dpc-4967	69	1	pmid	pmid	NOUN
dpc-4967	69	2	:	:	PUNCT
dpc-4967	69	3	37579248	37579248	NUM
dpc-4967	69	4	.	.	PUNCT
dpc-4967	70	1	3	3	X
dpc-4967	70	2	.	.	X
dpc-4967	70	3	litaiem	litaiem	ADJ
dpc-4967	70	4	n	n	CCONJ
dpc-4967	70	5	,	,	PUNCT
dpc-4967	70	6	mansour	mansour	PROPN
dpc-4967	70	7	y	y	PROPN
dpc-4967	70	8	,	,	PUNCT
dpc-4967	70	9	jones	jones	PROPN
dpc-4967	70	10	m	m	PROPN
dpc-4967	70	11	,	,	PUNCT
dpc-4967	70	12	et	et	PROPN
dpc-4967	70	13	al	al	PROPN
dpc-4967	70	14	.	.	PROPN
dpc-4967	70	15	dermoscopic	dermoscopic	PROPN
dpc-4967	70	16	signs	sign	NOUN
dpc-4967	70	17	of	of	ADP
dpc-4967	70	18	lichen	lichen	NOUN
dpc-4967	70	19	planus	planus	NOUN
dpc-4967	70	20	.	.	PUNCT
dpc-4967	71	1	bmj	bmj	PROPN
dpc-4967	71	2	case	case	NOUN
dpc-4967	71	3	rep	rep	PROPN
dpc-4967	71	4	.	.	PROPN
dpc-4967	71	5	2016;2016	2016;2016	NUM
dpc-4967	71	6	:	:	PUNCT
dpc-4967	71	7	bcr2015213923	bcr2015213923	NOUN
dpc-4967	71	8	.	.	PUNCT